Metsera (NASDAQ:MTSR) Hits New 12-Month Low – Here’s Why

Shares of Metsera, Inc. (NASDAQ:MTSR) hit a new 52-week low during trading on Wednesday . The stock traded as low as $22.29 and last traded at $22.43, with a volume of 150051 shares traded. The stock had previously closed at $24.51.

Analyst Ratings Changes

MTSR has been the topic of a number of research analyst reports. Cantor Fitzgerald began coverage on shares of Metsera in a report on Tuesday, February 25th. They issued an “overweight” rating on the stock. Guggenheim assumed coverage on Metsera in a report on Tuesday, February 25th. They issued a “buy” rating and a $56.00 target price on the stock. Evercore ISI assumed coverage on Metsera in a research report on Tuesday, February 25th. They set an “outperform” rating for the company. Finally, Bank of America initiated coverage on Metsera in a report on Tuesday, February 25th. They issued a “buy” rating and a $38.00 price objective on the stock.

Metsera Price Performance

Metsera (NASDAQ:MTSR) last announced its quarterly earnings results on Wednesday, March 26th. The company reported ($3.52) earnings per share for the quarter.

About Metsera

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.